Start with amyotrophic lateral sclerosis, then reuse UniProt P63316 as the stable protein anchor across project notes and exports.
CHEMBL2095202 Target Snapshot
Troponin, cardiac muscle · PROTEIN COMPLEX · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P63316. Start with amyotrophic lateral sclerosis, then reuse UniProt P63316 as the stable protein anchor across project notes and exports.
Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with amyotrophic lateral sclerosis because it currently carries late clinical support. Linked drugs include LEVOSIMENDAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTroponin C, slow skeletal and cardiac muscles
Review this target as Troponin, cardiac muscle, mapped to UniProt P63316. ChEMBL maps the protein component as Troponin C, slow skeletal and cardiac muscles. Sequence length is 161 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Troponin, cardiac muscle as ChEMBL target CHEMBL2095202, mapped to UniProt P63316. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Troponin, cardiac muscle is the right protein anchor across sources, using UniProt P63316 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why amyotrophic lateral sclerosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Troponin, cardiac muscle |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P63316 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Troponin C, slow skeletal and cardiac muscles |
| UniProt Accession | P63316 |
| Component Type | Protein |
| Sequence Length | 161 aa |
Troponin C, slow skeletal and cardiac muscles
How to read this target
Review this target as Troponin, cardiac muscle, mapped to UniProt P63316. ChEMBL maps the protein component as Troponin C, slow skeletal and cardiac muscles. Sequence length is 161 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with amyotrophic lateral sclerosis because it currently carries late clinical support. Linked drugs include LEVOSIMENDAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1581326 | 6.78 | EC50 | 165.07 | Preclinical |
| CHEMBL3195681 | 6.78 | EC50 | 164.57 | Preclinical |
| CHEMBL3195851 | 6.72 | EC50 | 190.67 | Preclinical |
| CHEMBL1468444 | 6.55 | EC50 | 278.85 | Preclinical |
| CHEMBL1379673 | 6.54 | EC50 | 286.87 | Preclinical |
| CHEMBL1477915 | 6.4 | EC50 | 396.99 | Preclinical |
| CHEMBL1398812 | 6.38 | EC50 | 413.02 | Preclinical |
| CHEMBL1369691 | 6.3 | EC50 | 500.48 | Preclinical |
| CHEMBL1573529 | 6.29 | EC50 | 515.79 | Preclinical |
| CHEMBL210208 | 6.25 | IC50 | 558.14 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 2 assays, 118 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 2 | 118 | 5.4 |